Search
01/05/2022
Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment
Reinoso-Segura, M, Caballero-Velazquez, T, Herrera, P, Patriarca, F, Fanin, R, Bruno, B, Einsele, H, Nahi, H, Granell, M, Lopez-Corral, L, Reguera, JL, Garcia-Cadenas, I, Gahrton, G, Perez-Simon, JA. Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. Transplantation And Cellular Therapy. 2022; 28(5)DOI:10.1016/j.jtct.2022.01.026. PMID:35131486. IF:3.200(Q2/5D).
25/04/2022
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
Orgueira, AM, Perez, MSG, Arias, JD, Rosinol, L, Oriol, A, Teruel, AI, Lopez, JM, Palomera, L, Granell, M, Blanchard, MJ, de la Rubia, J, de la Guia, AL, Rios, R, Sureda, A, Hernandez, MT, Bengoechea, E, Calasanz, MJ, Gutierrez, N, Martin, ML, Blade, J, Lahuerta, JJ, San Miguel, J, Mateos, MV. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. Blood Cancer Journal. 2022; 12(4)DOI:10.1038/s41408-022-00647-z. PMID:35468898. IF:12.800(Q1/1D).
19/04/2022
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Encinas, C, Hernandez-Rivas, JA, Oriol, A, Rosinol, L, Blanchard, MJ, Bellon, JM, Garcia-Sanz, R, de la Rubia, J, de la Guia, AL, Jimenez-Ubieto, A, Jarque, I, Inigo, B, Dourdil, V, de Arriba, F, Perez-Avila, CC, Gonzalez, Y, Hernandez, MT, Bargay, J, Granell, M, Rodriguez-Otero, P, Silvent, M, Cabrera, C, Rios, R, Alegre, A, Gironella, M, Gonzalez, MS, Sureda, A, Sampol, A, Ocio, EM, Krsnik, I, Garcia, A, Garcia-Mateo, A, Soler, JA, Martin, J, Arguinano, JM, Mateos, MV, Blade, J, San-Miguel, JF, Lahuerta, JJ, Martinez-Lopez, J. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. Blood Cancer Journal. 2022; 12(4)DOI:10.1038/s41408-022-00652-2. PMID:35440057. IF:12.800(Q1/1D).
01/03/2022
Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients
Ramos-Campoy, S, Puiggros, A, Bea, S, Bougeon, S, Larrayoz, MJ, Costa, D, Parker, H, Rigolin, GM, Ortega, M, Blanco, ML, Collado, R, Salgado, R, Baumann, T, Gimeno, E, Moreno, C, Bosch, F, Calvo, X, Calasanz, MJ, Cuneo, A, Strefford, JC, Nguyen-Khac, F, Oscier, D, Haferlach, C, Schoumans, J, Espinet, B. Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. HAEMATOLOGICA. 2022; 107(3)DOI:10.3324/haematol.2020.274456. PMID:33691382. IF:10.100(Q1/2D).
01/01/2022
Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges
Redondo, S, Esquirol, A, Novelli, S, Caballero, AC, Garrido, A, Onate, G, Lopez, J, Moreno, C, Saavedra, SD, Granell, M, Briones, J, Sierra, J, Martino, R, Garcia-Cadenas, I. Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges. Transplantation And Cellular Therapy. 2022; 28(1)DOI:10.1016/j.jtct.2021.10.015. PMID:34757054. IF:3.200(Q2/5D).
01/12/2024
Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation
Redondo, S, Garcia-Cadenas, I, Esquirol, A, Portos, JM, Iranzo, E, Arguello-Tomas, M, Saavedra, S, Oñate, G, Caballero, AC, Garrido, A, López, J, Muntañola, A, Paviglianiti, A, Miqueleiz, S, Sierra, J, Briones, J, Martino, R. Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation. EUROPEAN JOURNAL OF HAEMATOLOGY. 2024; 113(6)DOI:10.1111/ejh.14294. PMID:39155459. IF:2.300(Q2/5D).
01/10/2024
Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors plus Mycophenolate Mofetil versus Sirolimus plus Mycophenolate Mofetil
Esquirol, A, Pascual, MJ, Montoro, J, Piñana, JL, Ferrà, C, Herruzo, B, Garcia-Cadenas, I, Balaguer, A, Perez, A, Huguet, M, Redondo, S, Villalba, M, Hernandez-Boluda, JC, Chorao, P, Hernani, R, Sanz, J, Solano, C, Sierra, J, Martino, R. Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors plus Mycophenolate Mofetil versus Sirolimus plus Mycophenolate Mofetil. Transplantation And Cellular Therapy. 2024; 30(10)DOI:10.1016/j.jtct.2024.07.027. PMID:39116938. IF:4.400(Q1/1D).
14/09/2024
Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC
Salas, MQ, Cascos, E, López-García, A, Pérez-López, E, Baile-González, M, López-Corral, L, Cascón, MJP, Luque, M, Esquirol, A, Fernando, IH, Ormtegi, IO, Marin, AJS, Peña-Muñóz, F, Fernández-Luis, S, Domínguez-García, JJ, Fernández, SV, Girón, MFD, Pinedo, LG, González-Rodríguez, AP, Torrado, T, García, L, Filaferro, S, Cedillo, A, Basalobre, P, Ortí, G, Chacón, MJ. Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC. BONE MARROW TRANSPLANTATION. 2024; 59(12)DOI:10.1038/s41409-024-02414-z. PMID:39277653. IF:5.200(Q1/1D).